HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Bisacodyl (Bicol)

A diphenylmethane stimulant laxative used for the treatment of constipation and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)

Also Known As:

Bicol; Dulcolax; Agaroletten; Alophen Brand of Bisacodyl; Apo-Bisacodyl; Apotex Brand of Bisacodyl; Aventis Brand of Bisacodyl; Bekunis Bisacodyl; Bisac-Evac; Bisacodyl Tannex; Bisacodyl Uniserts; Bisalax; Bisco-Lax; Bisco-Zitron; Biscova Brand of Bisacodyl; Boehringer Ingelheim Brand of Bisacodyl; Dulco-Lax; Dulco-lax perles; Durolax; Fleet Bisacodyl; Fleet Brand of Bisacodyl; Florisan N; G & W Brand of Bisacodyl; Laxagetten; Laxanin; Laxans-ratiopharm; Laxbene; Laxysat Bürger; Lünolax; Lünopharm Brand of Bisacodyl; Merckle Brand of Bisacodyl; Novartis Brand of Bisacodyl; Numark Brand of Bisacodyl; Pfizer Consumer Healthcare Brand of Bisacodyl; Ratiopharm Brand of Bisacodyl; Richardson-Vicks Brand of Bisacodyl; Rytmil; Schein Brand of Bisacodyl; Schwarzhaupt Brand of Bisacodyl; Ulcolax; Ulmer Brand of Bisacodyl; Upsher-Smith Brand of Bisacodyl; Wallace Brand of Bisacodyl; Ysatfabrik Brand of Bisacodyl; ct-Arzneimittel Brand of Bisacodyl; ratio-Bisacodyl; roha Brand of Bisacodyl; Apo Bisacodyl; Bisac Evac; Bisacodyl Lünopharm Brand; Bisacodyl Richardson-Vicks Brand; Bisacodyl Upsher-Smith Brand; Bisacodyl, Bekunis; Bisacodyl, Fleet; Bisco Lax; Bisco Zitron; Dulco Lax; Dulco lax perles; Dulcolax perles; Laxans ratiopharm; Tannex, Bisacodyl; Uniserts, Bisacodyl; ratio Bisacodyl; Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)

Networked: 94 relevant articles (7 outcomes, 10 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Phenols: 309
  - Cresols: 7
    - Bisacodyl: 94

Experts

1.	Fontana, Paola: 2 articles (10/2015 - 09/2015)
2.	Manes, Gianpiero: 2 articles (10/2015 - 09/2015)
3.	Norton, Christine: 2 articles (01/2014 - 01/2013)
4.	Coggrave, Maureen: 2 articles (01/2014 - 01/2013)
5.	Ikarashi, Nobutomo: 2 articles (01/2013 - 11/2011)
6.	Benninga, Marc A: 2 articles (01/2012 - 01/2009)
7.	Tabbers, Merit M: 2 articles (01/2012 - 01/2009)
8.	Mueller-Lissner, Stefan: 2 articles (07/2011 - 09/2010)
9.	Kamm, Michael A: 2 articles (07/2011 - 04/2007)
10.	Tanha, Amir Saber: 1 article (12/2015)

Related Diseases

1.	Constipation 07/01/2011 - "All secondary end points (number of complete spontaneous bowel movements for each single week, number of spontaneous bowel movement (SBMs), and constipation-associated symptoms) differed significantly between groups, demonstrating efficacy for bisacodyl (P < .0001). " 07/01/2011 - "Compared with baseline, there was a statistically significant improvement in the overall Patient Assessment of Constipation quality of life (PAC-QOL) score and all subscales (satisfaction, physical discomfort, psychosocial discomfort, worries and concerns) in the bisacodyl-treated patients, compared with those that received placebo (P ≤ .0070). " 07/01/2011 - "Oral bisacodyl is an effective and well-tolerated treatment for patients with chronic constipation. " 05/15/2006 - "Bisacodyl is effective and safe in improving stool frequency and consistency in acute treatment of idiopathic constipation." 05/15/2006 - "Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study."
2.	Nausea 10/15/2007 - "The 10-mg bisacodyl regimen has an improved safety profile, with significantly reduced cramping, nausea and overall discomfort." 01/01/2011 - "Secondary outcome measures were stool consistency using the Bristol stool scale frequency of episodes of faecal incontinence, pain during defecation, frequency of abdominal pain, frequency of adverse effects (nausea, diarrhoea and bad taste), and frequency of intake of bisacodyl. " 01/01/2009 - "Secondary endpoints are stool consistency, faecal incontinence frequency, pain during defecation, digestive symptoms (abdominal pain, flatulence), adverse effects (nausea, diarrhoea, bad taste) and intake of rescue medication (Bisacodyl). " 03/01/2013 - "Patient-reported acceptability and tolerability for each item examined on the questionnaire was significantly greater for P/MC compared with 2L PEG-3350 and bisacodyl tablets (P<0.0001).Treatment-emergent AEs related to the bowel preparation reported by 1% of patients receiving P/MC or 2L PEG-3350 and bisacodyl tablets were nausea (3.0% vs. 4.3%), vomiting (1.4% vs. 2.0%), and headache (2.7% vs. 1.7%). " 01/01/2012 - "Compared with subjects in the NuLYTELY arm, subjects in the G/PEG without bisacodyl arm had less nausea (P<0.04), vomiting (P<0.02), abdominal pain (P<0.02), bloating (P<0.005), difficulty drinking the liquid (P<0.0001), and found the overall preparation easier to tolerate (P<0.0001). "
3.	Ileus 02/01/2009 - "All patients undergoing colorectal resection between November 2004 and February 2007 were assessed for inclusion into a prospective randomized trial investigating the influence of bisacodyl on postoperative ileus. " 12/01/2008 - "This prospective, randomized, double-blind trial investigates the effect of the colon-stimulating laxative bisacodyl on postoperative ileus in elective colorectal resections. " 07/01/2007 - "To compare the use of bisacodyl suppository with placebo in resolving postoperative ileus after elective colectomy in a randomized controlled trial. " 07/01/2007 - "Bisacodyl suppository seems to be effective and safe in resolving postoperative ileus after elective colectomy in colon cancer patients." 07/01/2007 - "Randomized controlled trial of bisacodyl suppository versus placebo for postoperative ileus after elective colectomy for colon cancer."
4.	Vomiting 10/01/2007 - "Patients receiving NaP tablets were significantly less likely to experience abdominal distention, abdominal pain, and vomiting than patients receiving PEG plus bisacodyl (P < 0.0012). " 03/01/2013 - "Patient-reported acceptability and tolerability for each item examined on the questionnaire was significantly greater for P/MC compared with 2L PEG-3350 and bisacodyl tablets (P<0.0001).Treatment-emergent AEs related to the bowel preparation reported by 1% of patients receiving P/MC or 2L PEG-3350 and bisacodyl tablets were nausea (3.0% vs. 4.3%), vomiting (1.4% vs. 2.0%), and headache (2.7% vs. 1.7%). " 01/01/2012 - "Compared with subjects in the NuLYTELY arm, subjects in the G/PEG without bisacodyl arm had less nausea (P<0.04), vomiting (P<0.02), abdominal pain (P<0.02), bloating (P<0.005), difficulty drinking the liquid (P<0.0001), and found the overall preparation easier to tolerate (P<0.0001). " 11/01/2000 - "Patients were asked to record the effects of the preparation, noting any vomiting, nausea, or abdominal pain, and to determine a discomfort rating on a scale of 1 to 5. One hundred sixty-nine patients were assigned to the oral sodium phosphate solution, and 154 to polyethylene glycol with bisacodyl. "
5.	Polyps 08/01/2009 - "The detection of polyps was significantly increased (p = 0.017) in the NaP group (43.1%) compared with the bisacodyl group (27.1%). " 09/01/2012 - "Bowel preparations for colonoscopy with PEG are significantly better than sodium phosphate and bisacodyl preparations, with higher BBPS scores and polyp detection rates." 12/01/2011 - "An intensive regimen consisting of a low-fiber diet, bisacodyl, and a split dose of polyethylene glycol can achieve good colon preparation with an improved detection rate for polyps and adenomas in most patients who have had poor bowel cleansing at a previous colonoscopy." 09/01/2012 - "Depending on bowel preparation, there were positive polyp findings in 40% of colonoscopies with PEG, 26% with sodium phosphates and 22% with bisacodyl (P = 0.01). "

Related Drugs and Biologics

1.	Polyethylene Glycols (Polyethylene Glycol)
2.	Sodium
3.	Tablets
4.	Suppositories (Vaginal Suppositories)
5.	Prostaglandins B (PGB)
6.	Cascara
7.	Lactulose (Duphalac)
8.	Azoxymethane
9.	Bisacodyl (Bicol)
10.	sennoside A&B (ND 10)

Related Therapies and Procedures

1.	Colectomy
2.	Enema (Enemas)
3.	Stents
4.	Oral Administration